top of page

Cardiff-based Draig Therapeutics launched today in the neuro space with a total investment of $140 million, with lead program DT-101, an AMPA receptor PAM, ready for P2 in Major Depressive Disorder

Jun 18, 2025
1 min read

Professor Simon Ward of Cardiff University’s Medicines Discovery Institute, and Scientific Co-founder and CSO Draig, describes the science behind the lead program and how the team has benefitted from work at Cardiff University's Brain Imaging Centre. The company will also develop GABA receptor targeting therapies.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page